• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    100.03 +1.62 (+1.65%)
    Streaming Delayed Price Updated: 10:20 AM EDT, Apr 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about BioNTech SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
    Issued on behalf of Oncolytics Biotech Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Achieves Minimum Condition in CureVac Exchange Offer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Host Innovation Series R&D Day on November 11, 2025
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
    From Pfizer Inc.
    Via Business Wire
    News headline image
    First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces Ryan Richardson to Step Down from the Management Board
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
    From BioNTech SE
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.